Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients With Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

NCT06359379 is registered in ClinicalTrials.gov with Shuttle Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06359379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06359379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients With Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Lead sponsor
Shuttle Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2024
Completion date
December 1, 2025
Enrollment
30 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh-wildtype